Janus Henderson Group PLC Has $954.83 Million Stake in Praxis Precision Medicines, Inc. $PRAX

Posted by Francis Steltz on Jun 18th, 2026

Janus Henderson Group PLC lifted its stake in shares of Praxis Precision Medicines, Inc. (NASDAQ:PRAX – Free Report) by 17.2% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 3,240,086 shares of the company’s stock after buying an additional 476,227 shares during the quarter. Janus Henderson Group PLC owned about 12.86% of Praxis Precision Medicines worth $954,834,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of PRAX. NBC Securities Inc. bought a new position in shares of Praxis Precision Medicines in the 4th quarter worth $38,000. Danske Bank A S bought a new position in shares of Praxis Precision Medicines in the 4th quarter worth $59,000. GAMMA Investing LLC lifted its holdings in shares of Praxis Precision Medicines by 58.7% in the 4th quarter. GAMMA Investing LLC now owns 238 shares of the company’s stock worth $70,000 after purchasing an additional 88 shares in the last quarter. Tower Research Capital LLC TRC lifted its holdings in shares of Praxis Precision Medicines by 24.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 1,837 shares of the company’s stock worth $77,000 after purchasing an additional 359 shares in the last quarter. Finally, Farther Finance Advisors LLC lifted its stake in Praxis Precision Medicines by 60.0% during the 4th quarter. Farther Finance Advisors LLC now owns 368 shares of the company’s stock valued at $108,000 after acquiring an additional 138 shares in the last quarter. Institutional investors and hedge funds own 67.84% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on the company. Jefferies Financial Group restated a “buy” rating on shares of Praxis Precision Medicines in a research note on Thursday, May 7th. Royal Bank Of Canada assumed coverage on Praxis Precision Medicines in a research note on Wednesday. They set an “outperform” rating and a $449.00 price objective on the stock. Truist Financial set a $616.00 price objective on Praxis Precision Medicines and gave the company a “buy” rating in a research note on Tuesday, June 2nd. BTIG Research restated a “buy” rating and set a $810.00 price objective (down from $843.00) on shares of Praxis Precision Medicines in a research note on Tuesday, June 2nd. Finally, Robert W. Baird dropped their price objective on Praxis Precision Medicines from $433.00 to $400.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 2nd. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $566.21.

View Our Latest Stock Analysis on PRAX

Praxis Precision Medicines Price Performance

NASDAQ PRAX opened at $270.01 on Thursday. The stock has a market capitalization of $7.53 billion, a price-to-earnings ratio of -20.20 and a beta of 2.71. Praxis Precision Medicines, Inc. has a one year low of $37.19 and a one year high of $366.52. The business’s fifty day moving average is $316.54 and its 200-day moving average is $302.97.

Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) last released its earnings results on Thursday, May 7th. The company reported ($3.20) EPS for the quarter, topping analysts’ consensus estimates of ($3.58) by $0.38. Research analysts expect that Praxis Precision Medicines, Inc. will post -14.79 EPS for the current fiscal year.

Praxis Precision Medicines Profile

(Free Report)

Praxis Precision Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing precision therapies for disorders driven by neuronal excitability. The company applies translational neuroscience and genetic insights to design small molecule drugs that target specific ion channels and receptor subtypes implicated in neurological and psychiatric conditions. Its research aims to address unmet needs in rare epilepsies, essential tremor, treatment-resistant depression and other central nervous system (CNS) disorders.

The company’s pipeline includes several lead candidates at various stages of development.